Therapy News and Research

RSS

Complete Response letter related to the BLA for azficel-T offered to Fibrocell Science

Fibrocell Science, Inc. announced today that it has received a Complete Response letter from the U.S. Food and Drug Administration (FDA) related to the Biologics License Application (BLA) for azficel-T, an autologous cell therapy for the treatment of moderate to severe nasolabial fold wrinkles in adults.

22 Dec 2009

LEO Pharma announces positive results for two Phase III AK clinical trials

LEO Pharma today announced positive results for the company’s two Phase III actinic (solar) keratosis (AK) clinical trials using PEP005 (ingenol mebutate) Gel for the treatment of lesions on head treatment areas, which include the face and scalp.

22 Dec 2009

BUSM researchers discover new gene therapy for treating emphysema patients

Researchers from Boston University School of Medicine (BUSM) have discovered a new gene therapy that may prevent the progression of emphysema. The study, which appears on-line in the Journal of Clinical Investigation, describes a method to express therapeutic genes in lung tissue for a lifetime after only a single treatment.

22 Dec 2009

Results from Phase I trial of Bryan Oncor's targeted radiopharmaceutical therapy reported

Bryan Oncor reports the results of a Phase I trial of its targeted radiopharmaceutical therapy using Re-88 P2045, a radiolabeled synthetic peptide, for the treatment of advanced lung cancer.

21 Dec 2009

Clarient announces acquisition of Applied Genomics

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that it has acquired privately held, Huntsville, AL-based Applied Genomics, Inc. (AGI) in an all-stock merger valued at up to $17.6 million, if all conditions and milestones set forth in the merger agreement are successfully met.

21 Dec 2009

Effectiveness of VSEL stem cells in regenerative medicine demonstrated at the ASH meeting

NeoStem, Inc. (NYSE Amex: NBS), which is a leading provider of pre-disease adult stem cell collection, processing and long-term storage services, and holds the exclusive, worldwide license to VSEL(TM) technology that uses very small embryonic-like stem cells isolated from peripheral blood, announced today that five posters and two oral presentations at the prestigious American Society of Hematology (ASH) Annual Meeting in New Orleans in early December demonstrated the basic cellular mechanisms of very small embryonic-like stem cells.

21 Dec 2009

Bioject Medical Technologies completes a Series G Preferred Stock financing

Bioject Medical Technologies Inc., a leading developer of needle-free injection therapy systems, today announced that on December 18, 2009, it completed a Series G Preferred Stock financing with each of Life Sciences Opportunities Fund II, L.P., Life Sciences Opportunities Fund (Institutional) II, L.P. (collectively, the “LOF”), and Edward Flynn for the purchase of an aggregate of 92,448 shares of its Series G Convertible Preferred Stock at a price of $13.00 per share.

21 Dec 2009

Teva Pharmaceutical Industries, OncoGenex Pharmaceuticals announce collaboration in cancer therapy

Teva Pharmaceutical Industries Ltd. and OncoGenex Pharmaceuticals, Inc. announced today that they have entered into a global license and collaboration agreement to develop and commercialize OGX-011, as well as an agreement to purchase shares in OncoGenex. OGX-011 is a Phase III cancer therapy designed to inhibit cancer treatment resistance.

21 Dec 2009

CPEX Pharmaceuticals completes enrollment in Nasulin Phase 2a clinical trial

CPEX Pharmaceuticals, Inc. today announced that the ongoing Phase 2a clinical trial of Nasulin™, the Company’s intranasal insulin candidate, has now completed enrollment. The study was initiated in February of this year and randomized 94 subjects. Results are expected at the end of the first quarter or beginning of the second quarter of 2010.

21 Dec 2009

Soligenix commences SGX201 Phase 1/2 clinical trial for acute radiation enteritis prevention

Soligenix, Inc., formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced today that it has initiated a Phase 1/2 clinical trial evaluating SGX201, a time-release formulation of oral beclomethasone 17,21-dipropionate (oral BDP), for the prevention of acute radiation enteritis.

21 Dec 2009

Evidence Based Associates presents award to the FFT/Redirection program

On November 12, 2009, Evidence Based Associates presented an award to the FFT/Redirection program at the Institute for Child & Family Health. The Redirection Program is a community-based, family-centered alternative to residential juvenile justice commitment programs.

21 Dec 2009

Preliminary results from Phase III study of afamelanotide in EPP announced

Clinuvel Pharmaceuticals Limited today announced that it has obtained promising 4-months results in testing afamelanotide in a multicentre randomised double-blind placebo controlled Phase III study in EPP (CUV017).

21 Dec 2009

Researchers follow steps that lead some tumor cells to establish metastases

Up to 25% of cancer patients develop metastases in the brain - often long after successful treatment of the primary tumor. In almost all such cases, the prognosis is poor. The mechanisms responsible for the appearance of brain metastases have long been mysterious.

21 Dec 2009

$4.2M Medicare fraud: Three Detroit-area residents plead guilty

Jackson, Mich., resident Terrence Hicks and Detroit residents Muhammed Al Mahdi and John Saunders pleaded guilty in U.S. District Court in the Eastern District of Michigan this week for their roles in a $4.2 million Medicare fraud scheme, Assistant Attorney General Lanny A. Breuer of the Criminal Division, Acting U.S. Attorney Terrence Berg of the Eastern District of Michigan, Special Agent in Charge Andrew G. Arena of the FBI's Detroit Field Office and Daniel R. Levinson, Inspector General of the Department of Health and Human Services (HHS) announced today.

19 Dec 2009

Medical physicists converge at ProCure TDC for training in physics of protons and proton therapy

Medical physicists from around the world converged at the ProCure Training and Development Center (TDC) last week for intense training in the physics of protons and proton therapy, an alternative to X-ray radiation for cancer treatment that spares healthy tissue and results in far fewer short- and long-term treatment side effects.

19 Dec 2009

Ontario surpasses federal target for radiation therapy

For the past 12 months, Ontario has surpassed the federal target for radiation therapy wait times, demonstrating that the province has continued to improve access to this important cancer treatment.

19 Dec 2009

Children with type 1 diabetes benefit from rapid-acting insulin analogues; potential harm remains unclear

Due to a lack of suitable studies, it remains unclear whether children and adolescents with type 1 diabetes benefit more or less from long-term treatment with rapid-acting insulin analogues than with short-acting human insulin.

19 Dec 2009

Subitizing vision therapy for improving math skills

"The incidence of individuals with a mathematics learning disability is between 6-7% of the population." Since there are more than 300 million individuals in the United States, up to 21 million men, women, and children may be affected by this disorder. Sidney Groffman OD, MA, FCOVD, Professor Emeritus at SUNY College of Optometry, author of the article published in the December 2009 issue of Optometry & Vision Development, also says, "This is unfortunate because math skills are of prime importance in everyday life enabling us to understand number concepts and do calculations. Math ability is essential for many occupations and professions."

19 Dec 2009

Applied Technology Holdings opens new 25,000-square-foot facility in California

Applied Technology Holdings, Inc., today announced the opening of its new headquarters in Mission Viejo, California. The new 25,000-square-foot facility will bring employees from its MVP Sports Technologies and Applied Medical Group Subsidiaries together into one Mission Viejo neighborhood, and will enhance the collaboration between ATH's Physical Therapy, Medical, Sports, Product Design, Strategy, and Technology groups.

19 Dec 2009

Only half of eligible heart failure patients receive implantable devices

A study of heart failure patients who meet national guidelines for devices that stabilize and strengthen the heart's electrical system found that only half of eligible patients received the devices.

19 Dec 2009

Therapy News and Research

Complete Response letter related to the BLA for azficel-T offered to Fibrocell Science

LEO Pharma announces positive results for two Phase III AK clinical trials

BUSM researchers discover new gene therapy for treating emphysema patients

Results from Phase I trial of Bryan Oncor's targeted radiopharmaceutical therapy reported

Clarient announces acquisition of Applied Genomics

Effectiveness of VSEL stem cells in regenerative medicine demonstrated at the ASH meeting

Bioject Medical Technologies completes a Series G Preferred Stock financing

Teva Pharmaceutical Industries, OncoGenex Pharmaceuticals announce collaboration in cancer therapy

CPEX Pharmaceuticals completes enrollment in Nasulin Phase 2a clinical trial

Soligenix commences SGX201 Phase 1/2 clinical trial for acute radiation enteritis prevention

Evidence Based Associates presents award to the FFT/Redirection program

Preliminary results from Phase III study of afamelanotide in EPP announced

Researchers follow steps that lead some tumor cells to establish metastases

$4.2M Medicare fraud: Three Detroit-area residents plead guilty

Medical physicists converge at ProCure TDC for training in physics of protons and proton therapy

Ontario surpasses federal target for radiation therapy

Children with type 1 diabetes benefit from rapid-acting insulin analogues; potential harm remains unclear

Subitizing vision therapy for improving math skills

Applied Technology Holdings opens new 25,000-square-foot facility in California

Only half of eligible heart failure patients receive implantable devices

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News